Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitolisant for EDS in Obstructive Sleep Apnea
NCT05223166Phase 3Completed
- Sponsor
- Citrine Medicine
- Start
- Apr 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea (OSA) comparing Pitolisant with Placebo (2 arms). Primary endpoint: Epworth Sleepiness Scale at 12 weeks. Started Apr 2022; status: completed.
02
Drugs
pitolisant
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05223166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223166.